Full year report 2012 - Nobel Biocare Corporate

Income statementin EUR ‘000 Note Q4 2012 Q4 2011 FY 2012 FY 2011Revenue 6 152’994 154’621 580’485 569’179Cost of goods sold –38’255 –37’406 –143’003 –136’677Gross profit 114’739 117’215 437’482 432’502Selling and marketing expenses 1 –69’557 –66’066 –259’536 –252’219Administrative expenses 1 –20’518 –20’077 –74’252 –79’152Research and development expenses –10’346 –8’028 –35’008 –29’005Profit from operations (EBIT) 14’318 23’044 68’686 72’126Financial income 7 683 414 1’207 2’335Finance cost 7 –2’338 –3’882 –9’076 –14’318Net foreign exchange result 7 1’123 –883 178 –4’674Profit before tax 13’786 18’693 60’995 55’469Income tax expenses –2’636 –5’428 –15’146 –15’688Profit attributable to owners of Nobel Biocare 11’150 13’265 45’849 39’781Basic earnings per share (EUR) 0.09 0.11 0.37 0.32Diluted earnings per share (EUR) 0.09 0.11 0.37 0.321 Certain comparatives have been reclassified from administrative to selling and marketing expenses.Statement of comprehensive incomein EUR ‘000 Note Q4 2012 Q4 2011 FY 2012 FY 2011Profit attributable to owners of Nobel Biocare 11’150 13’266 45’849 39’781Other comprehensive income:Foreign currency translation differences –4’916 17’913 523 –37’276Effective portion of changes in fair valueof net investment hedges 867 – –633 –Reclassification of foreign currency translationdifferences to income statement, net of tax 7 – 508 – 1’217Effective portion of changes in fair valueof cash flow hedges, net of tax 1’158 –257 3’474 –6’397Net change in fair value of cash flow hedgesreclassified to income statement, net of tax 7 –490 109 1’315 –2’649Total other comprehensive income/(expenses)for the period, net of tax –3’381 18’273 4’679 –45’105Total comprehensive income/(expenses) for theperiod attributable to owners of Nobel Biocare 7’769 31’539 50’528 –5’324Full year report 201212/21